预约演示

更新于：2025-05-07

Glioma

胶质瘤

更新于：2025-05-07

基本信息

别名

GLIOMA、GLIOMAS、Glial Cell Tumor

+ [36]

简介

Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)

关联

1,620

项与胶质瘤相关的药物

Mirdametinib

靶点

MEK1 x MEK2

作用机制

MEK1抑制剂 [+1]

在研机构

BeiGene Ltd. [+1]

原研机构

Springworks Therapeutics, Inc.

在研适应症

神经纤维瘤病1型 [+13]

非在研适应症

晚期乳腺癌 [+6]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2025-02-11

Bevacizumab biosimilar(Shanghai Institute of Biological Products)

贝伐珠单抗生物类似药(上海生物制品研究所)

靶点

VEGF-A

作用机制

VEGF-A抑制剂 [+1]

在研机构

上海生物制品研究所有限责任公司

原研机构

上海生物制品研究所有限责任公司

在研适应症

输卵管癌 [+8]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2025-01-08

18F-PSMA-1007

氟[18]-PSMA-1007

靶点

PSMA

作用机制

PSMA调节剂

在研机构

ABX advanced biochemical compounds GmbH [+2]

原研机构

German Cancer Research Center

在研适应症

前列腺癌 [+2]

非在研适应症

胶质母细胞瘤

最高研发阶段批准上市

首次获批国家/地区

韩国

首次获批日期2024-12-11

4,114

项与胶质瘤相关的临床试验

NCT02864888

/ Not yet recruiting临床3期IIT

A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugenal (AS2-1)] on the QT/QTc Interval In Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma

The primary objective of this protocol study is to investigate the effect of Antineoplaston therapy on the QT/QTc interval in study subjects age 3 to 21 years with newly-diagnosed, diffuse, intrinsic brainstem glioma. This investigation is to be conducted in parallel with a phase 3 efficacy and safety study of combination Antineoplaston therapy + radiation vs. radiation alone (BRI-BT-52).

开始日期2027-06-01

申办/合作机构

Burzynski Research Institute, Inc.

NCT04933422

/ Not yet recruiting临床1期

Phase 1 Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Effects of CM93 in Subjects With Recurrent Glioblastoma (rGBM) Characterized by Epidermal Growth Factor Receptor (EGFR) Mutation or Amplification

This is a first-in-human study of CM93, an oral investigational drug, in adults with Epidermal Growth Factor Receptor-modified glioblastoma. The study is designed in three parts consisting of a dose-escalation phase, a dose-expansion phase and a window-of-opportunity surgical trial. The trial objectives are to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical effects of CM93 in this patient population.

开始日期2027-01-01

申办/合作机构

Crimson BioPharm, Inc.

NCT04903795

/ Not yet recruiting临床1期IIT

A Phase I Study of hEGFRvIII-CD3 Bi-scFv (BRiTE) in Patients With WHO Grade IV Malignant Glioma

This phase 1 study will evaluate a novel hEGFRvIII-CD3-biscFv Bispecific T cell engager (BRiTE) in patients diagnosed with pathologically documented World Health Organization (WHO) grade 4 malignant glioma (MG) with an EGFRvIII (epidermal growth factor receptor variant III) mutation (either newly diagnosed or at first progression/recurrence). The primary objective is to evaluate the safety of BRiTE in such patients.

开始日期2026-12-01

申办/合作机构

Duke University

100 项与胶质瘤相关的临床结果

登录后查看更多信息

100 项与胶质瘤相关的转化医学

登录后查看更多信息

0 项与胶质瘤相关的专利（医药）

登录后查看更多信息

143,214

项与胶质瘤相关的文献（医药）

2025-12-31·Artificial Cells, Nanomedicine, and Biotechnology

Statement of Retraction: Myricetin nanoliposomes induced SIRT3-mediated glycolytic metabolism leading to glioblastoma cell death

Article

2025-12-31·OncoImmunology

EphA2 and phosphoantigen-mediated selective killing of medulloblastoma by γδT cells preserves neuronal and stem cell integrity

Article

作者: Wilhelm, Margareta T ; Liu, Mingzhi ; Bedoya-Reina, Oscar ; Boutin, Lola ; Déchanet Merville, Julie

Medulloblastoma (MB) is a pediatric brain tumor that develops in the cerebellum, representing one of the most common malignant brain cancers in children. Standard treatments include surgery, chemotherapy, and radiation, but despite a 5-y survival rate of approximately 70%, these therapies often lead to significant neurological damage in the developing brain. This underscores the urgent need for less toxic, more effective therapeutic alternatives. Recent advancements in cancer immunotherapy, including immune checkpoint inhibitors and CAR-T cell therapy, have revolutionized cancer treatment. One promising avenue is the use of Gamma Delta (γδ)T cells, a unique T cell population with potential advantages, such as non-alloreactivity, potent tumor cell lysis, and broad antigen recognition. However, their capacity to recognize and target MB cells remains underexplored. To investigate the therapeutic potential of γδT cells against MB, we analyzed the proportion and status of MB-infiltrated γδT cells within patient datasets. We next investigated the expression of γδT cell ligands on MB cells and identified the EphA2 receptor and the phosphoantigen/Butyrophilin complex as key ligands, activating Vγ9 Vδ1 and Vγ9 Vδ2 T cells, respectively, leading to significant MB cell lysis in both monolayer and spheroid models. Importantly, preliminary safety data showed that γδT cells did not target differentiated neurons or neuroepithelial stem cells derived from induced pluripotent stem cells, underscoring the selectivity and safety of this approach. In conclusion, γδT cells trigger an efficient and specific killing of MB and would offer a promising novel therapeutic strategy.

2025-12-31·Artificial Cells, Nanomedicine, and Biotechnology

IRES activation: HK2 and TPI1 glycolytic enzymes play a pivotal role in non-neuronal cell survival under hypoxia

Article

作者: Devi, Sushma ; Hussain, Mahboob-Ul- ; Arora, Poonam ; Rahamathulla, Mohamed ; Banday, Muddasir Sharief ; Kumar, Manish ; Shivanandappa, Thippeswamy Boreddy ; Najar, Imtiyaz Ahmed ; Pasha, Ismail ; Ismail, Rehana ; Ahmed, Mohammed Muqtader

Hypoxia-induced brain damage can cause consciousness, memory failure and death. HK2 and TPI1 were investigated to see how they change hypoxia sensitivity in neurons and non-neurons. Hypoxia sensitivity is determined by the differential overexpression of both important glycolytic enzymes in neuronal and non-neuronal cells. C6 glioma cells expressed greater HK2 and TPI1 protein than neuro 2A cells, which were more sensitive to hypoxia-induced cell death by MTT and lactate dehydrogenase leakage assay. After 48 h of hypoxia, C6 glioma cells displayed substantial protein upregulation of HK2 and TPI1 glycolytic proteins but not mRNA. Hypoxia did not raise HK2 and TPI1 mRNA transcription, pointing at post-transcriptional protein regulation. Using di-cistronic and promoter-less di-cistronic assays, we discovered significant IRES regions in HK2 and TPI1 mRNA's 5'UTR, more active in C6 glioma cells with polypyrimidine tract binding (PTB) protein. We concluded that non-neuronal cells varied in HK2 and TPI1 overexpression, altering their vulnerability to hypoxia-induced cell death. Adjusting HK2, TP1 and PTB levels may prevent hypoxia-induced brain cell death. These results offer new information on glycolytic enzyme modulation under hypoxia, crucial for comprehending cell survival in hypoxic situations. This could affect situations like neurodegenerative illnesses or ischaemic injuries, where hypoxia-induced cell death is crucial.

5,703

项与胶质瘤相关的新闻（医药）

2025-05-04

·梅斯医学

在医学影像界，CT好比诊室里的“显微镜”和“探照灯”，是医生用来侦查体内“隐秘角落”的神兵利器。无论是急诊创伤、肺炎排查，还是癌症分期、术前评估，CT几乎“无所不能”。近年来，技术升级的速度更是堪比电子产品换代”，图像更清晰、速度更快、覆盖更广，CT早已稳坐临床检查的C位。但“神器”也有代价。CT使用的电离辐射，虽然看不见摸不着，却可能在细胞深处种下变异的种子。《柳叶刀-肿瘤学》（The Lancet Oncology）一项研究[1]曾指出，儿童和青少年接受CT检查后，脑部辐射剂量与脑癌风险呈线性关系，尤其是胶质瘤发病率显著上升；发表于《自然-医学》（Nature Medicine）的一项研究[2]也发现，CT检查次数与血液系统恶性肿瘤风险成正比，每多做一次，风险上升达43％。不过，这些研究的视角基本聚焦在22岁以下的年轻群体。那成年人呢？中老年人呢？医院里排队等CT的，可远不止孩子。这也是JAMA Internal Medicine最近发表的一项重磅研究[3]的突破所在：它将“电离辐射致癌”的风险评估扩展至全人群，从儿童到老年人，一个不落。研究数据显示，仅在2023年，美国就完成了9300万次CT扫描，覆盖约6150万人。而由这些CT带来的潜在辐射致癌风险，可能导致10.27万例未来癌症——这相当于美国每年新发癌症病例的5％！9300万次CT，6151万人上“机”扫描如果说医院是一座城市，那CT室无疑是其中最忙碌的“交通枢纽”之一。我们来做个简单的数学题：9300万次检查 ÷ 6151万患者 = 平均每人1.5次CT。换句话说，有不少人一年不止“上机”一次，有些甚至是“两刷”或“三刷”。不过，CT检查的年龄分配比例有所不同——成年人是这场影像浪潮中的绝对主力军。CT检查的辐射，真的有这么“毒”？这时候可能有人会好奇：“儿童做CT的次数不是很少吗，为什么风险也这么高？”虽然儿童只占所有CT检查量的3.3％，但他们的组织还在发育，细胞分裂速度快，对电离辐射异常敏感。就像刚发芽的小树苗，哪怕只晒了一点点烈日，也更容易留下伤痕。那么，这些“潜伏”的癌症到底藏在哪里？这些类型与CT检查的频率和辐射暴露的部位高度相关——例如胸部CT常用于肺部疾病排查，腹盆部CT则是消化系统“标配”。这并不奇怪，儿童常做头颈部CT，甲状腺又是对辐射最敏感的器官之一。如果细分到不同年龄段来看，每次CT检查相关的癌症风险在婴幼儿时期最高，随着年龄增长而逐渐降低。然而，这并不意味着成年群体就“安全无虞”。虽然单次CT辐射的癌症风险在成人中相对较低，但由于成人接受CT检查的总次数远高于儿童，因此其总体癌症病例数仍然高居不下。原因很简单：这一年龄段常常面临慢性病管理、术前评估、肿瘤筛查……说白了，CT的使用频率居高不下。这也提示我们，CT检查的时候，儿童“单位风险”更高，成年人“总量风险”更大。研究人员强调：如果当前CT的使用频率和辐射剂量水平保持不变，其带来的潜在致癌风险，已经可以和酒精（5.4％）或肥胖（7.6％）这类常见风险因素“平起平坐”。儿童和年轻人中CT相关辐射暴露与脑癌相关当然，谈论辐射的风险不能脱离剂量这个前提。正如那句老话所说——“抛开剂量谈毒性，都是耍流氓。”的确，每次接受CT扫描时，辐射剂量远未达到会立刻造成伤害的水平，单次风险几乎可以忽略不计。但问题的关键，不在“这一次”，而在于“这许多次”的累积效应。就像一锅水，一开始微温，摸上去甚至觉得舒适；可如果不断地反复加热，温度一点点上升，最终也可能达到让人难以承受的高温。CT检查中的辐射暴露，某种程度上也是类似的道理——每次不多，但多次积累之后，就值得警惕。这并非危言耸听。《柳叶刀-肿瘤学》（The Lancet Oncology）发表的一项覆盖欧洲九国、追踪近66万人的超大规模前瞻性队列研究（EPI-CT）[1]就量化了CT检查在儿童和年轻人中引发的脑癌风险。每多做一次CT，患血液恶性肿瘤的风险高43％随之而来的另一个关键问题是，低剂量辐射会不会存在什么健康隐患？另一项发表于Nature Medicine的研究[2]就评估了CT扫描的低剂量辐射与罹患血液系统恶性肿瘤风险的关联。这些结果表明，即便单次CT检查产生的辐射剂量有限，随着检查次数的累积，其对患者健康的负面影响会逐渐放大。冷静看待，科学应对不少人看到这些研究结果后，开始有点慌了：是不是以后都不能做CT了？其实，大可不必恐慌。我们并不是要劝退大家做CT检查，更不是在妖魔化CT。综合多项研究来看，真正需要警惕的，并不是单次检查，而是——频繁进行CT扫描，尤其在短期内反复检查，所带来的累积辐射暴露。关于辐射剂量与癌症风险的关系，权威机构也已经有了清晰的态度。根据国际辐射防护委员会（ICRP）的评估，在累积有效剂量低于100 mSv时，目前流行病学证据尚不足以确认癌症风险的显著增加。但基于LNT模型（假设即使是极低剂量也有一定风险），仍建议审慎对待，默认风险存在[4]。而世界卫生组织（WHO）则指出，一旦累积电离辐射剂量超过100 mSv，患癌风险将显著上升[5]。这也是为何，在研究[1]中，研究人员一再强调：CT检查在辅助临床诊断中具有不可替代的价值，关键在于——合理选择，必要时做，并在检查中优化辐射剂量，做到“用得好、用得巧”。简单来说，不是拒绝CT，而是要用得恰到好处。那么，一次CT检查的辐射量到底有多少？根据美国放射学会（ACR）等权威机构数据[6-8]，不同类型的CT检查有效剂量大致如下：由此看来，如果短期内多次扫描，累积剂量就可能逐步接近乃至超过100 mSv，风险便不容小觑。因此，每一次CT检查，都需要医生综合评估其必要性，合理权衡利弊，避免不必要的重复检查；而患者自身，也应主动告知病史（包括近期是否做过CT），不要为了“放心”而盲目要求增加CT扫描。CT是把双刃剑，用得合理，它是救命的神器；用得过度，才可能带来不必要的隐患。科学理性使用，保护健康才是王道。仍需指出的是，上述几项研究尚不能直接推断因果关系。参考资料：[1]Hauptmann M, Byrnes G, Cardis E, Bernier MO, Blettner M, Dabin J, Engels H, Istad TS, Johansen C, Kaijser M, Kjaerheim K, Journy N, Meulepas JM, Moissonnier M, Ronckers C, Thierry-Chef I, Le Cornet L, Jahnen A, Pokora R, Bosch de Basea M, Figuerola J, Maccia C, Nordenskjold A, Harbron RW, Lee C, Simon SL, Berrington de Gonzalez A, Schüz J, Kesminiene A. Brain cancer after radiation exposure from CT examinations of children and young adults: results from the EPI-CT cohort study. Lancet Oncol. 2023 Jan;24(1):45-53. doi: 10.1016/S1470-2045(22)00655-6. Epub 2022 Dec 6. PMID: 36493793.[2]Bosch de Basea Gomez, M., Thierry-Chef, I., Harbron, R. et al. Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adults. Nat Med 29, 3111–3119 (2023). https://doi.org/10.1038/s41591-023-02620-0[3]Smith-Bindman R,Chu PW, Azman Firdaus H, et al. Projected Lifetime Cancer Risks From Current Computed Tomography Imaging. JAMA Intern Med. Published online April 14, 2025. doi:10.1001/jamainternmed.2025.0505[4]https://www.icrp.org/publication.asp?id=ICRP%20Publication%20103[5]https://www.who.int/news-room/fact-sheets/detail/ionizing-radiation-and-health-effects[6]American College of Radiology. ACR Appropriateness Criteria (2020)[7]UNSCEAR. Sources and Effects of Ionizing Radiation (2008)[8]National Council on Radiation Protection. Report No.184 (2019)撰文 | 木白编辑 | 木白● 微创手术花了393元，患者嫌贵，吐槽被医院忽悠了！医生回应：想要得到救治，又不想花钱，检查多一点就是忽悠你？烫个头也得几百呢● 每天多喝一杯咖啡，肺癌增加6%？最新研究：经常喝咖啡，肺癌风险飙升54％，女性甚至高达101%！● 热议！饶毅：请勿错怪王辰教授，4+4没有问题！公众并非质疑制度创新本身，关键这是否为少数人留下了“钻空子”和“权力寻租”的机会？版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

2025-05-03

·赛柏蓝

这46家药企最赚钱！恒瑞、云南白药、百利天恒、华东医药...

编者按：本文来自米内网，作者苍穹；赛柏蓝授权转载，编辑相宜踏入5月，上市公司2024年业绩基本披露完毕，年度最会赚钱的医药企业名单也随之出炉。截至4月30日，2024年净利润超过10亿元的A股医药企业共有46家，合计净利润在1200亿元以上；其中，迈瑞、恒瑞、云南白药、上药等6家企业均以超40亿元的净利润位居前列；达仁堂、浙江医药、百利天恒等6家企业净利润增长均超过100%；22家企业净利润创新高，包括华润三九、华东等首度突破30亿大关的潜力者，以及国药现代、西藏药业等首次晋身10亿梯次的生力军。2024年净利润超过10亿元的A股医药企业01医疗药械龙头116亿净利润出圈76亿分红创新高作为国产医疗药械龙头，迈瑞医疗2024年实现营业收入367.26亿元，同比增长5.14%；净利润116.68亿元，同比增长0.74%。自公司上市以来，迈瑞医疗营收和净利润已保持连续7年的双增长。分红预案显示，迈瑞医疗拟向全体股东每10股派5.6元（含税），共计派发现金红利约6.79亿元。加上2024年已实施的中期利润分配和第二次中期利润分配，2024年度公司累计现金分红总额将达到76.02亿元，现金分红比例为65.15%，分红总金额再创历史新高。过去的2024年，其已完成“设备+IT+AI”的智能医疗生态系统搭建，推出全球首个临床落地的重症医疗大模型——启元重症医疗大模型，并通过“三瑞”生态与设备的融合创新，结合大数据、人工智能，为医疗机构提供全院级数智化整体解决方案，用技术手段解决优质医疗资源分布不均的痛点，助力全球医疗机构提升诊疗能力和运营效率，同时提高其在全球高端客户群的渗透率和品牌粘性。对于国际市场局部面临宏观环境和地缘政治带来的挑战，迈瑞医疗表示，得益于海外高端客户群的持续突破、本地化平台能力建设的逐步完善，以及全球各主要地区收入的均衡分布，特别是在发展中国家和欧洲市场强劲表现的拉动下，其国际业务收入有望在未来几年内不断提升。02净利润涨超47%恒瑞医药创新成果丰硕素有“创新药一哥”之称的恒瑞医药，2024年实现营业收入279.85亿元，同比增22.63%；净利润63.37亿元，同比增47.28%；拟向全体股东按每10股派发现金股利2.00元（含税），为自上市以来第25次派现分红。近年来，恒瑞医药创新成果持续涌现，临床价值凸显，驱动收入增长。2024年创新药销售收入达138.92亿元（含税，不含对外许可收入），同比增长30.60%，创新药销售收入占总销售收入（不含对外许可收入）一半以上，研发投入占销售收入比重达29.40%，至今恒瑞累计研发投入已超过460亿元。为保证创新产出，恒瑞不断加大创新力度，2024年研发投入达82.28亿元，其中费用化研发投入65.83亿元，截至目前，已有约20款1类新药在国内获批上市。BD国际化加速推进，恒瑞已累计实现15笔创新药海外授权合作，其中近三年合计对外授权项目数占比过半，包括多笔总交易金额在10亿美元以上的项目。03云南白药净赚47亿核心单品销量节节攀升云南白药2024年实现营业收入400.33亿元，同比增长2.36%；净利润47.49亿元，同比增长16.02%，业绩再现双增。基于良好的业绩表现及发展质效，云南白药持续提升股东回报水平，2024年度拟派发现金红利21.14亿元，2024年三季度已实施的特别分红21.64亿元，以上现金分红累计总额达42.79亿元，占全年净利润的90.09%。2024年，云南白药进一步聚焦工业板块。药品事业群方面，销售额过亿的产品达10个，其中云南白药气雾剂大涨26%，蒲地蓝消炎片、气血康口服液分别涨超22%和14%，云南白药膏、云南白药胶囊等均实现显著增长；中药资源事业群持续保障战略品种的供应与价格稳定，三七提取物销售继续保持市场领先水平；健康品事业群净利润同比增长8.36%，口腔护理及防脱洗护领域稳健发展。云南白药将创新研发作为高质量发展的底层支撑：布局气血康口服液、云南白药胶囊等11个中药大品种、25个项目的二次创新开发；推进云南白药透皮制剂、全三七片、附杞固本膏等创新中药开发；聚焦创新药研发成果转化，如INR101（前列腺癌患者PSMA阳性病灶PET成像）、INR102（转移性去势抵抗性前列腺癌）已分别步入Ⅲ期和Ⅰ/Ⅱa期临床，KA-1641（肿瘤恶病质）处于临床前研究阶段。04华润三九净利润首破30亿中药传承创新成绩斐然华润三九2024年交出了一份营收利润双增、且均创新高的答卷，公司实现营业收入276.17亿元，同比增长11.63%；净利润33.68亿元，同比增长18.05%。公司拟向全体股东每10股派送现金3.2元（含税），预计派发现金红利4.11亿元。在复杂的经济和市场环境下，华润三九2024年继续锚定战略方向，坚持“品牌+创新”双轮驱动。自我诊疗（CHC）业务成绩亮眼：999感冒灵、抗病毒口服液等大品种市场持续扩大，冰连清咽喷雾剂、玉屏风口服液等新品快速打开市场；中药传承创新成果显著：4个经典名方获批上市，包括首个进入医保目录的妇科经典名方温经汤颗粒；多款新药临床试验稳步推进：1类新药KYAZ01-2011-020（急性脑卒中）、CR999C1905L1（抗肿瘤）、CR999C2016L1（胶质瘤）等已进入Ⅰ期临床及以上阶段，2类改良型新药CR999K1601L1（胃癌根治术淋巴示踪）、CR999C1701L1（痤疮）等已进入Ⅲ期临床。此外，华润三九通过“内生+外延”双向发力，持续完善产业布局。其收购昆药集团后，2024年完成对华润圣火51%股权的收购，强化三七产业链掌控力。目前昆药集团净利润贡献占比达22.3%，其慢病管理业务与公司CHC板块形成协同。随着其对天士力28%股权收购，有望进一步补充其心脑血管创新中药管线。05浙江医药净利润暴增170%子公司表现可圈可点浙江医药2024年实现营业收入93.75亿元，同比增长20.29%；净利润11.61亿元，同比增长170.11%。其拟每10股派发红利3.7元（含税），预计现金分红3.56亿元，占净利润比例为30.66%。作为国内维矿领域的“扛把子”，浙江医药表示，2024年其主导产品维生素E和维生素A市场价格和需求上升，利润进一步增长；生命营养品和药品两大主营业务板块销售实现双涨，推动整体营收增长，进而带动利润提升；优化成本费用结构，研发费用下降12.87%，销售费用维持平稳，使其保持较高的利润水平。浙江医药多个子公司在2024年表现出彩，合力为业绩贡献增量。其中，子公司芳原馨生物通过优化间甲酚各相关中间体生产工艺，综合完工成本下降；子公司新码生物积极推进1类新药ARX788（HER2 ADC）的生产许可证取证工作，ARX305（CD70 ADC）Ⅰ期临床试验正进行中，NCB003（长效IL-2药物）获得临床试验默示许可；子公司新昌制药厂的1类新药SH-337（治疗消化系统酸相关性疾病）、LYSC98（由革兰阳性菌引起的细菌性皮肤和软组织感染）等已相继获批临床。来源：东方财富网、公司年报；注：统计日期截至4月30日，如有疏漏，欢迎指正！END内容沟通：郑瑶（13810174402）

财报

2025-05-03

·PRNewswire

RaySearch Laboratories and Vision RT present innovations in surface guided treatment planning at ESTRO

STOCKHOLM, May 3, 2025 /PRNewswire/ -- At this week's ESTRO conference in Vienna, RaySearch Laboratories AB (publ) and Vision RT proudly announces the next step in their collaboration: the full integration of MapRT with RayStation®* treatment planning system. This integration enables full access to the MapRT clearance map in RayStation to guide the user during treatment planning in choosing beam trajectories clear from collisions between the treatment unit, patient and couch. During CT simulation, MapRT cameras capture the entire surface of the patient, along with any immobilization accessories. The MapRT software then analyzes this data, alongside models of the treatment couch and machine, to identify safe gantry and couch angles which are represented by a clearance map that is immediately accessible in RayStation. The integration is designed to optimize beam options for better plans and minimize the need for dry runs. This is particularly important for treatment plans where the couch is rotated. Recent studies have demonstrated that non-coplanar treatments can significantly improve treatment plans for several cancers, including lung1,2,3,4, breast5,6,7,8, head and neck cancers9,10,11,12,13, lymphoma14,15, and high-grade glioma16. These treatments can offer clinically relevant benefits, such as improved organ-at-risk dose sparing. Helen Convery, Senior Dosimetrist (Development & Clinical Trials), who has tested the integration, says: "We have used MapRT at Raigmore Hospital since 2022 and have found it invaluable for checking for collision on all plans and optimizing non-coplanar plan angles. I think the integration into RayStation is of significant value and I can see it further streamlining and improving the efficiency of our workflow." Thomas Carter, VP of Marketing, Vision RT, adds: "We are already seeing clinics changing their planning techniques, allowing their patients to benefit from the extra beam options MapRT provides. This integration has the potential to streamline workflows, reduce errors, and free up resources, all while improving treatment predictability. It also opens the path for automated, collision-free planning." Björn Hårdemark, Deputy CEO, RaySearch: "Surface scanning is an excellent source of information about the most central aspect of radiation therapy – the patient. The tight integration between MapRT and RayStation makes this information available already during treatment planning, allowing the user to explore more creative beam configurations while maintaining clearance around the patient. It is a great example of how clinical benefit can be achieved through collaboration between radiation therapy technology vendors." MapRT is approved for CE marking and clinical distribution in the EU and UK. A version without the API is currently cleared for sale in the USA, with API version 510(k) pending. About Vision RT Vision RT is the inventor of Surface Guided Radiation Therapy (SGRT) which uses camera systems to track surface data, to offer more guidance across every step of the radiotherapy workflow: simulation, planning, treatment and dose visualization. We work tirelessly to improve the accuracy, efficiency, safety and comfort of radiation therapy. Vision RT is part of the William Demant Invest (WDI) family, a leading Danish Medtech investor with a long-term investment perspective. The companies in WDI employ more than 21,000 people. About RaySearch RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. RaySearch's software has been sold to over 1,100 clinics in 47 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com. About RayStation RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved. * Subject to regulatory clearance in some markets. For more information, please contact: Johan Löf, founder and CEO, RaySearch Laboratories AB (publ) Telephone: +46 (0) 8 510 530 00 [email protected]  Learn more about us on: LinkedIn YouTube [1] Ma M, Ren W, Li M, Niu C, Dai J. Dosimetric comparison of coplanar and non-coplanar beam arrangements for radiotherapy of patients with lung cancer: A meta-analysis. J Appl Clin Med Phys. 2021 Apr;22(4):34-43. doi: 10.1002/acm2.13197. Epub 2021 Feb 26. PMID: 33634946; PMCID: PMC8035566. [2] Kim ST, An HJ, Kim JI, Yoo JR, Kim HJ, Park JM. Non-coplanar VMAT plans for lung SABR to reduce dose to the heart: a planning study. Br J Radiol. 2020 Jan;93(1105):20190596. doi: 10.1259/bjr.20190596. Epub 2019 Oct 22. PMID: 31625759; PMCID: PMC6948076. [3] Lincoln JD, MacDonald RL, Syme A, Thomas CG. Static couch non-coplanar arc selection optimization for lung SBRT treatment planning. Phys Med Biol. 2023 Jul 21;68(15). doi: 10.1088/1361-6560/ace23f. PMID: 37369237. [4]Chapet O, Khodri M, Jalade P, N'guyen D, Flandin I, D'hombres A, Romestaing P, Mornex F. Potential benefits of using non-coplanar field and intensity modulated radiation therapy to preserve the heart in irradiation of lung tumors in the middle and lower lobes. Radiother Oncol. 2006 Sep;80(3):333-40. doi: 10.1016/j.radonc.2006.07.009. Epub 2006 Aug 24. PMID: 16934354. [5] J, F., et al. (2023). Locoregional breast radiotherapy including IMN: optimizing the dose distribution using an automated non-coplanar VMAT-technique. Acta oncologica (Stockholm, Sweden), [online] 62(10). doi:. [6] Xu, Y., Ma, P., Hu, Z., Tian, Y., Men, K., Wang, S., Xu, Y. and Dai, J. (2021). Non-coplanar volumetric modulated arc therapy for locoregional radiotherapy of left-sided breast cancer including internal mammary nodes. Radiology and Oncology, 55(4), pp.499–507. doi:. [7] A, B., et al. (2023). Dosimetric Comparision of Coplanar versus Non-coplanar Volumetric Modulated Arc Therapy for Treatment of Bilateral Breast Cancers. Journal of medical physics, [online] 48(3). doi:. [8] Biau J, Lopez L, Thivat E, Casile M, Millardet C, Saroul N, Pham-Dang N, Molnar I, Bourhis J, Lapeyre M. Postoperative SBRT in the treatment of early-stage oropharyngeal and oral cavity cancers with high-risk margins: A dosimetric comparison of volumetric modulated arc therapy with or without non-coplanar arcs and acute toxicity outcomes from the STEREOPOSTOP GORTEC 2017-03 phase 2 trial. Clin Transl Radiat Oncol. 2022 Nov 14;38:169-174. doi: 10.1016/j.ctro.2022.11.07. PMID: 36466746; PMCID: PMC9712819. [9]Woods KE, Ma TM, Cook KA, Morris ED, Gao Y, Sheng K, Kishan AU, Hegde JV, Felix C, Basehart V, Narahara K, Shen Z, Tenn S, Steinberg ML, Chin RK, Cao M. A Prospective Phase II Study of Automated Non-Coplanar VMAT for Recurrent Head and Neck Cancer: Initial Report of Feasibility, Safety, and Patient-Reported Outcomes. Cancers (Basel). 2022 Feb 14;14(4):939. doi: 10.3390/cancers14040939. PMID: 35205686; PMCID: PMC8870161. [10] Gayen S, Kombathula SH, Manna S, Varshney S, Pareek P. Dosimetric comparison of coplanar and non-coplanar volumetric-modulated arc therapy in head and neck cancer treated with radiotherapy. Radiat Oncol J. 2020 Jun;38(2):138-147. doi: 10.3857/roj.2020.00143. Epub 2020 May 26. PMID: 33012157; PMCID: PMC7533406. [11] Gayen S, Kombathula SH, Manna S, Varshney S, Pareek P. Dosimetric comparison of coplanar and non-coplanar volumetric-modulated arc therapy in head and neck cancer treated with radiotherapy. Radiat Oncol J. 2020 Jun;38(2):138-147. doi: 10.3857/roj.2020.00143. Epub 2020 May 26. PMID: 33012157; PMCID: PMC7533406. [12] Subramanian VS, Subramani V, Chilukuri S, Kathirvel M, Arun G, Swamy ST, Subramanian K, Fogliata A, Cozzi L. Multi-isocentric 4π volumetric-modulated arc therapy approach for head and neck cancer. J Appl Clin Med Phys. 2017 Sep;18(5):293-300. doi: 10.1002/acm2.12164. Epub 2017 Aug 20. PMID: 28834021; PMCID: PMC5874945. [13] Wild, E., Bangert, M., Nill, S. and Oelfke, U. (2015). Non-coplanar VMAT for nasopharyngeal tumors: Plan quality versus treatment time. Medical Physics, 42(5), pp.2157–2168. doi:. [14] Rossi L, Cambraia Lopes P, Marques Leitão J, Janus C, van de Pol M, Breedveld S, Penninkhof J, Heijmen BJM. On the Importance of Individualized, Non-Coplanar Beam Configurations in Mediastinal Lymphoma Radiotherapy, Optimized With Automated Planning. Front Oncol. 2021 Apr 15;11:619929. doi: 10.3389/fonc.2021.619929. PMID: 33937025; PMCID: PMC8082440. [15] Chen X, Jin D, Wang S, Li M, Huang P, Dai J. Non-coplanar intensity-modulated radiation therapy for young female patients with mediastinal lymphoma. J Appl Clin Med Phys. 2012 Nov 8;13(6):3769. doi: 10.1120/jacmp.v13i6.3769. PMID: 23149772; PMCID: PMC5718536. [16] Yu VY, Landers A, Woods K, Nguyen D, Cao M, Du D, Chin RK, Sheng K, Kaprealian TB. A Prospective 4π Radiation Therapy Clinical Study in Recurrent High-Grade Glioma Patients. Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):144-151. doi: 10.1016/j.ijrobp.2018.01.048. Epub 2018 Jan 31. PMID: 29619962. This information was brought to you by Cision The following files are available for download: SOURCE RaySearch Laboratories WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

放射疗法临床2期